The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Presented by American Medical Association{beacon} Health Care Health Care   The Big Story Democratic urge Musk to keep ‘hands ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

But the results add to evidence from animal studies and reports that people are finding drugs like Ozempic and Wegovy helpful to manage cravings, not just for food, but also for tobacco and alcohol.

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

Why does Hims seem to be able to ignore the statutes and rules that are enforced by the FDA and followed by every other ...